首页 > 最新文献

Journal of Biomedical Science最新文献

英文 中文
Targeting NLRP3 signaling reduces myocarditis-induced arrhythmogenesis and cardiac remodeling 靶向 NLRP3 信号可减少心肌炎诱发的心律失常和心脏重塑
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-22 DOI: 10.1186/s12929-024-01032-7
Chye-Gen Chin, Yao-Chang Chen, Fong-Jhih Lin, Yung-Kuo Lin, Yen-Yu Lu, Tzu-Yu Cheng, Shih-Ann Chen, Yi-Jen Chen
Myocarditis substantially increases the risk of ventricular arrhythmia. Approximately 30% of all ventricular arrhythmia cases in patients with myocarditis originate from the right ventricular outflow tract (RVOT). However, the role of NLRP3 signaling in RVOT arrhythmogenesis remains unclear. Rats with myosin peptide–induced myocarditis (experimental group) were treated with an NLRP3 inhibitor (MCC950; 10 mg/kg, daily for 14 days) or left untreated. Then, they were subjected to electrocardiography and echocardiography. Ventricular tissue samples were collected from each rat’s RVOT, right ventricular apex (RVA), and left ventricle (LV) and examined through conventional microelectrode and histopathologic analyses. In addition, whole-cell patch-clamp recording, confocal fluorescence microscopy, and Western blotting were performed to evaluate ionic currents, intracellular Ca2+ transients, and Ca2+-modulated protein expression in individual myocytes isolated from the RVOTs. The LV ejection fraction was lower and premature ventricular contraction frequency was higher in the experimental group than in the control group (rats not exposed to myosin peptide). Myocarditis increased the infiltration of inflammatory cells into cardiac tissue and upregulated the expression of NLRP3; these observations were more prominent in the RVOT and RVA than in the LV. Furthermore, experimental rats treated with MCC950 (treatment group) improved their LV ejection fraction and reduced the frequency of premature ventricular contraction. Histopathological analysis revealed higher incidence of abnormal automaticity and pacing-induced ventricular tachycardia in the RVOTs of the experimental group than in those of the control and treatment groups. However, the incidences of these conditions in the RVA and LV were similar across the groups. The RVOT myocytes of the experimental group exhibited lower Ca2+ levels in the sarcoplasmic reticulum, smaller intracellular Ca2+ transients, lower L-type Ca2+ currents, larger late Na+ currents, larger Na+–Ca2+ exchanger currents, higher reactive oxygen species levels, and higher Ca2+/calmodulin-dependent protein kinase II levels than did those of the control and treatment groups. Myocarditis may increase the rate of RVOT arrhythmogenesis, possibly through electrical and structural remodeling. These changes may be mitigated by inhibiting NLRP3 signaling.
心肌炎会大大增加室性心律失常的风险。在心肌炎患者的所有室性心律失常病例中,约有 30% 源自右室流出道 (RVOT)。然而,NLRP3 信号在 RVOT 心律失常发生中的作用仍不清楚。用 NLRP3 抑制剂(MCC950;10 毫克/千克,每天一次,连续 14 天)治疗或不治疗肌球蛋白肽诱导的心肌炎大鼠(实验组)。然后对它们进行心电图和超声心动图检查。从每只大鼠的 RVOT、右心室顶(RVA)和左心室(LV)采集心室组织样本,并通过常规微电极和组织病理学分析进行检查。此外,还进行了全细胞膜片钳记录、共聚焦荧光显微镜和 Western 印迹分析,以评估从 RVOT 分离的单个心肌细胞中的离子电流、细胞内 Ca2+ 瞬态和 Ca2+ 调制蛋白的表达。与对照组(未接触肌球蛋白肽的大鼠)相比,实验组的左心室射血分数较低,室性早搏频率较高。心肌炎增加了炎症细胞对心脏组织的浸润,并上调了 NLRP3 的表达;这些观察结果在 RVOT 和 RVA 比在 LV 更为突出。此外,接受 MCC950 治疗的实验鼠(治疗组)的左心室射血分数有所提高,室性早搏的频率也有所降低。组织病理学分析显示,实验组大鼠 RVOT 自动异常和起搏诱发的室性心动过速的发生率高于对照组和治疗组。然而,这些情况在 RVA 和 LV 的发生率在各组中相似。与对照组和治疗组相比,实验组 RVOT 心肌细胞的肌浆网中 Ca2+ 水平较低、细胞内 Ca2+ 瞬态较小、L 型 Ca2+ 电流较低、晚期 Na+ 电流较大、Na+-Ca2+ 交换电流较大、活性氧水平较高、Ca2+/钙调蛋白依赖性蛋白激酶 II 水平较高。心肌炎可能会通过电气和结构重塑增加 RVOT 心律失常的发生率。抑制 NLRP3 信号传导可减轻这些变化。
{"title":"Targeting NLRP3 signaling reduces myocarditis-induced arrhythmogenesis and cardiac remodeling","authors":"Chye-Gen Chin, Yao-Chang Chen, Fong-Jhih Lin, Yung-Kuo Lin, Yen-Yu Lu, Tzu-Yu Cheng, Shih-Ann Chen, Yi-Jen Chen","doi":"10.1186/s12929-024-01032-7","DOIUrl":"https://doi.org/10.1186/s12929-024-01032-7","url":null,"abstract":"Myocarditis substantially increases the risk of ventricular arrhythmia. Approximately 30% of all ventricular arrhythmia cases in patients with myocarditis originate from the right ventricular outflow tract (RVOT). However, the role of NLRP3 signaling in RVOT arrhythmogenesis remains unclear. Rats with myosin peptide–induced myocarditis (experimental group) were treated with an NLRP3 inhibitor (MCC950; 10 mg/kg, daily for 14 days) or left untreated. Then, they were subjected to electrocardiography and echocardiography. Ventricular tissue samples were collected from each rat’s RVOT, right ventricular apex (RVA), and left ventricle (LV) and examined through conventional microelectrode and histopathologic analyses. In addition, whole-cell patch-clamp recording, confocal fluorescence microscopy, and Western blotting were performed to evaluate ionic currents, intracellular Ca2+ transients, and Ca2+-modulated protein expression in individual myocytes isolated from the RVOTs. The LV ejection fraction was lower and premature ventricular contraction frequency was higher in the experimental group than in the control group (rats not exposed to myosin peptide). Myocarditis increased the infiltration of inflammatory cells into cardiac tissue and upregulated the expression of NLRP3; these observations were more prominent in the RVOT and RVA than in the LV. Furthermore, experimental rats treated with MCC950 (treatment group) improved their LV ejection fraction and reduced the frequency of premature ventricular contraction. Histopathological analysis revealed higher incidence of abnormal automaticity and pacing-induced ventricular tachycardia in the RVOTs of the experimental group than in those of the control and treatment groups. However, the incidences of these conditions in the RVA and LV were similar across the groups. The RVOT myocytes of the experimental group exhibited lower Ca2+ levels in the sarcoplasmic reticulum, smaller intracellular Ca2+ transients, lower L-type Ca2+ currents, larger late Na+ currents, larger Na+–Ca2+ exchanger currents, higher reactive oxygen species levels, and higher Ca2+/calmodulin-dependent protein kinase II levels than did those of the control and treatment groups. Myocarditis may increase the rate of RVOT arrhythmogenesis, possibly through electrical and structural remodeling. These changes may be mitigated by inhibiting NLRP3 signaling.","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"49 1","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140637320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dengue virus pathogenesis and host molecular machineries 登革热病毒发病机制和宿主分子机制
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-22 DOI: 10.1186/s12929-024-01030-9
Saumya Sinha, Kinjal Singh, Y. S. Ravi Kumar, Riya Roy, Sushant Phadnis, Varsha Meena, Sankar Bhattacharyya, Bhupendra Verma
Dengue viruses (DENV) are positive-stranded RNA viruses belonging to the Flaviviridae family. DENV is the causative agent of dengue, the most rapidly spreading viral disease transmitted by mosquitoes. Each year, millions of people contract the virus through bites from infected female mosquitoes of the Aedes species. In the majority of individuals, the infection is asymptomatic, and the immune system successfully manages to control virus replication within a few days. Symptomatic individuals may present with a mild fever (Dengue fever or DF) that may or may not progress to a more critical disease termed Dengue hemorrhagic fever (DHF) or the fatal Dengue shock syndrome (DSS). In the absence of a universally accepted prophylactic vaccine or therapeutic drug, treatment is mostly restricted to supportive measures. Similar to many other viruses that induce acute illness, DENV has developed several ways to modulate host metabolism to create an environment conducive to genome replication and the dissemination of viral progeny. To search for new therapeutic options, understanding the underlying host-virus regulatory system involved in various biological processes of the viral life cycle is essential. This review aims to summarize the complex interaction between DENV and the host cellular machinery, comprising regulatory mechanisms at various molecular levels such as epigenetic modulation of the host genome, transcription of host genes, translation of viral and host mRNAs, post-transcriptional regulation of the host transcriptome, post-translational regulation of viral proteins, and pathways involved in protein degradation.
登革病毒(DENV)是属于黄病毒科的正链 RNA 病毒。DENV 是登革热的病原体,登革热是由蚊子传播最迅速的病毒性疾病。每年都有数百万人因被伊蚊类受感染的雌蚊叮咬而感染该病毒。大多数人感染登革热后没有症状,免疫系统会在几天内成功控制病毒复制。无症状者可能会出现轻度发烧(登革热或 DF),可能会也可能不会发展成更严重的疾病,即登革出血热(DHF)或致命的登革休克综合征(DSS)。由于缺乏普遍接受的预防性疫苗或治疗药物,治疗主要限于支持性措施。与其他许多诱发急性疾病的病毒类似,登革热病毒已开发出多种调节宿主新陈代谢的方法,以创造有利于基因组复制和病毒后代传播的环境。要寻找新的治疗方案,就必须了解病毒生命周期中各种生物过程所涉及的宿主-病毒调控系统。本综述旨在总结 DENV 与宿主细胞机制之间复杂的相互作用,包括不同分子水平的调控机制,如宿主基因组的表观遗传调控、宿主基因的转录、病毒和宿主 mRNA 的翻译、宿主转录组的转录后调控、病毒蛋白的翻译后调控以及参与蛋白降解的途径。
{"title":"Dengue virus pathogenesis and host molecular machineries","authors":"Saumya Sinha, Kinjal Singh, Y. S. Ravi Kumar, Riya Roy, Sushant Phadnis, Varsha Meena, Sankar Bhattacharyya, Bhupendra Verma","doi":"10.1186/s12929-024-01030-9","DOIUrl":"https://doi.org/10.1186/s12929-024-01030-9","url":null,"abstract":"Dengue viruses (DENV) are positive-stranded RNA viruses belonging to the Flaviviridae family. DENV is the causative agent of dengue, the most rapidly spreading viral disease transmitted by mosquitoes. Each year, millions of people contract the virus through bites from infected female mosquitoes of the Aedes species. In the majority of individuals, the infection is asymptomatic, and the immune system successfully manages to control virus replication within a few days. Symptomatic individuals may present with a mild fever (Dengue fever or DF) that may or may not progress to a more critical disease termed Dengue hemorrhagic fever (DHF) or the fatal Dengue shock syndrome (DSS). In the absence of a universally accepted prophylactic vaccine or therapeutic drug, treatment is mostly restricted to supportive measures. Similar to many other viruses that induce acute illness, DENV has developed several ways to modulate host metabolism to create an environment conducive to genome replication and the dissemination of viral progeny. To search for new therapeutic options, understanding the underlying host-virus regulatory system involved in various biological processes of the viral life cycle is essential. This review aims to summarize the complex interaction between DENV and the host cellular machinery, comprising regulatory mechanisms at various molecular levels such as epigenetic modulation of the host genome, transcription of host genes, translation of viral and host mRNAs, post-transcriptional regulation of the host transcriptome, post-translational regulation of viral proteins, and pathways involved in protein degradation.","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"51 1","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140637200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applications of peptides in nanosystems for diagnosing and managing bacterial sepsis 肽在纳米系统中的应用:诊断和控制细菌性败血症
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-19 DOI: 10.1186/s12929-024-01029-2
Mohammed A. Gafar, Calvin A. Omolo, Eman Elhassan, Usri H. Ibrahim, Thirumala Govender
Sepsis represents a critical medical condition stemming from an imbalanced host immune response to infections, which is linked to a significant burden of disease. Despite substantial efforts in laboratory and clinical research, sepsis remains a prominent contributor to mortality worldwide. Nanotechnology presents innovative opportunities for the advancement of sepsis diagnosis and treatment. Due to their unique properties, including diversity, ease of synthesis, biocompatibility, high specificity, and excellent pharmacological efficacy, peptides hold great potential as part of nanotechnology approaches against sepsis. Herein, we present a comprehensive and up-to-date review of the applications of peptides in nanosystems for combating sepsis, with the potential to expedite diagnosis and enhance management outcomes. Firstly, sepsis pathophysiology, antisepsis drug targets, current modalities in management and diagnosis with their limitations, and the potential of peptides to advance the diagnosis and management of sepsis have been adequately addressed. The applications have been organized into diagnostic or managing applications, with the last one being further sub-organized into nano-delivered bioactive peptides with antimicrobial or anti-inflammatory activity, peptides as targeting moieties on the surface of nanosystems against sepsis, and peptides as nanocarriers for antisepsis agents. The studies have been grouped thematically and discussed, emphasizing the constructed nanosystem, physicochemical properties, and peptide-imparted enhancement in diagnostic and therapeutic efficacy. The strengths, limitations, and research gaps in each section have been elaborated. Finally, current challenges and potential future paths to enhance the use of peptides in nanosystems for combating sepsis have been deliberately spotlighted. This review reaffirms peptides' potential as promising biomaterials within nanotechnology strategies aimed at improving sepsis diagnosis and management. • Due to their unique characteristics, Peptides hold significant promise as part of nanotechnology approaches for diagnosing and treating sepsis, a current leading global killer. • Various diagnostic nanotools utilizing peptides as pathogen recognition moieties can improve the pathogen capturing efficiency for sepsis diagnosis. • Nano-delivery can overcome the limitations of bioactive peptides and enhance their antibacterial and anti-inflammatory efficacy in sepsis management. • Peptides offer significant capabilities as targeting moieties and nanocarriers to augment the effectiveness of antisepsis agents. • Future research identified can potentiate the applications of peptides for the diagnosis and treatment of sepsis.
败血症是一种严重的医疗状况,源于宿主对感染的免疫反应失衡,与严重的疾病负担有关。尽管在实验室和临床研究方面做出了巨大努力,败血症仍然是造成全球死亡的一个主要因素。纳米技术为败血症的诊断和治疗带来了创新机遇。由于肽具有独特的特性,包括多样性、易于合成、生物相容性、高特异性和卓越的药理功效,因此肽作为抗脓毒症纳米技术的一部分具有巨大的潜力。在此,我们将对肽在纳米系统中抗击脓毒症的应用进行全面和最新的综述,以期加快诊断和提高治疗效果。首先,我们充分论述了败血症病理生理学、抗败血症药物靶点、目前的管理和诊断模式及其局限性,以及肽在推进败血症诊断和管理方面的潜力。肽的应用分为诊断应用和管理应用,最后一种应用又分为具有抗菌或抗炎活性的纳米生物活性肽、肽作为抗败血症纳米系统表面的靶向分子以及肽作为防腐剂的纳米载体。这些研究按主题进行了分组和讨论,强调了所构建的纳米系统、理化特性以及肽对诊断和治疗效果的促进作用。还阐述了每个部分的优势、局限性和研究空白。最后,还特意强调了在纳米系统中加强多肽在抗脓毒症方面的应用所面临的挑战和未来可能的发展方向。这篇综述再次肯定了多肽作为纳米技术战略中前景广阔的生物材料在改善败血症诊断和管理方面的潜力。- 由于其独特的特性,多肽有望成为诊断和治疗败血症这一全球头号杀手的纳米技术方法的一部分。- 利用肽作为病原体识别分子的各种纳米诊断工具可以提高败血症诊断中病原体捕获效率。- 纳米给药可以克服生物活性肽的局限性,提高其在败血症治疗中的抗菌和消炎功效。- 肽作为靶向分子和纳米载体,在增强防腐剂的有效性方面具有重要作用。- 未来的研究发现,肽在败血症诊断和治疗中的应用将更加有效。
{"title":"Applications of peptides in nanosystems for diagnosing and managing bacterial sepsis","authors":"Mohammed A. Gafar, Calvin A. Omolo, Eman Elhassan, Usri H. Ibrahim, Thirumala Govender","doi":"10.1186/s12929-024-01029-2","DOIUrl":"https://doi.org/10.1186/s12929-024-01029-2","url":null,"abstract":"Sepsis represents a critical medical condition stemming from an imbalanced host immune response to infections, which is linked to a significant burden of disease. Despite substantial efforts in laboratory and clinical research, sepsis remains a prominent contributor to mortality worldwide. Nanotechnology presents innovative opportunities for the advancement of sepsis diagnosis and treatment. Due to their unique properties, including diversity, ease of synthesis, biocompatibility, high specificity, and excellent pharmacological efficacy, peptides hold great potential as part of nanotechnology approaches against sepsis. Herein, we present a comprehensive and up-to-date review of the applications of peptides in nanosystems for combating sepsis, with the potential to expedite diagnosis and enhance management outcomes. Firstly, sepsis pathophysiology, antisepsis drug targets, current modalities in management and diagnosis with their limitations, and the potential of peptides to advance the diagnosis and management of sepsis have been adequately addressed. The applications have been organized into diagnostic or managing applications, with the last one being further sub-organized into nano-delivered bioactive peptides with antimicrobial or anti-inflammatory activity, peptides as targeting moieties on the surface of nanosystems against sepsis, and peptides as nanocarriers for antisepsis agents. The studies have been grouped thematically and discussed, emphasizing the constructed nanosystem, physicochemical properties, and peptide-imparted enhancement in diagnostic and therapeutic efficacy. The strengths, limitations, and research gaps in each section have been elaborated. Finally, current challenges and potential future paths to enhance the use of peptides in nanosystems for combating sepsis have been deliberately spotlighted. This review reaffirms peptides' potential as promising biomaterials within nanotechnology strategies aimed at improving sepsis diagnosis and management. • Due to their unique characteristics, Peptides hold significant promise as part of nanotechnology approaches for diagnosing and treating sepsis, a current leading global killer. • Various diagnostic nanotools utilizing peptides as pathogen recognition moieties can improve the pathogen capturing efficiency for sepsis diagnosis. • Nano-delivery can overcome the limitations of bioactive peptides and enhance their antibacterial and anti-inflammatory efficacy in sepsis management. • Peptides offer significant capabilities as targeting moieties and nanocarriers to augment the effectiveness of antisepsis agents. • Future research identified can potentiate the applications of peptides for the diagnosis and treatment of sepsis.","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"28 1","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140628948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19 COVID-19患者体内ACE2交叉反应性抗SARS-CoV-2 RBD抗体对NETosis的增强作用
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-18 DOI: 10.1186/s12929-024-01026-5
Kun-Han Hsieh, Chiao-Hsuan Chao, Yi-Ling Cheng, Yen-Chung Lai, Yung-Chun Chuang, Jen-Ren Wang, Sui-Yuan Chang, Yuan-Pin Hung, Yi-Ming Arthur Chen, Wei-Lun Liu, Woei-Jer Chuang, Trai-Ming Yeh
High levels of neutrophil extracellular trap (NET) formation or NETosis and autoantibodies are related to poor prognosis and disease severity of COVID-19 patients. Human angiotensin-converting enzyme 2 (ACE2) cross-reactive anti-severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain (SARS-CoV-2 RBD) antibodies (CR Abs) have been reported as one of the sources of anti-ACE2 autoantibodies. However, the pathological implications of CR Abs in NET formation remain unknown. In this study, we first assessed the presence of CR Abs in the sera of COVID-19 patients with different severity by serological analysis. Sera and purified IgG from CR Abs positive COVID-19 patients as well as a mouse monoclonal Ab (mAb 127) that can recognize both ACE2 and the RBD were tested for their influence on NETosis and the possible mechanisms involved were studied. An association between CR Abs levels and the severity of COVID-19 in 120 patients was found. The CR Abs-positive sera and IgG from severe COVID-19 patients and mAb 127 significantly activated human leukocytes and triggered NETosis, in the presence of RBD. This NETosis, triggered by the coexistence of CR Abs and RBD, activated thrombus-related cells but was abolished when the interaction between CR Abs and ACE2 or Fc receptors was disrupted. We also revealed that CR Abs-induced NETosis was suppressed in the presence of recombinant ACE2 or the Src family kinase inhibitor, dasatinib. Furthermore, we found that COVID-19 vaccination not only reduced COVID-19 severity but also prevented the production of CR Abs after SARS-CoV-2 infection. Our findings provide possible pathogenic effects of CR Abs in exacerbating COVID-19 by enhancing NETosis, highlighting ACE2 and dasatinib as potential treatments, and supporting the benefit of vaccination in reducing disease severity and CR Abs production in COVID-19 patients.
高水平的中性粒细胞胞外捕获物(NET)形成或NETosis和自身抗体与COVID-19患者的不良预后和疾病严重程度有关。据报道,人类血管紧张素转换酶 2(ACE2)交叉反应性抗严重急性呼吸系统综合征冠状病毒 2 尖峰蛋白受体结合域(SARS-CoV-2 RBD)抗体(CR Abs)是抗ACE2自身抗体的来源之一。然而,CR Abs在NET形成过程中的病理影响仍然未知。在本研究中,我们首先通过血清学分析评估了不同严重程度的 COVID-19 患者血清中 CR Abs 的存在情况。我们检测了 CR Abs 阳性 COVID-19 患者的血清和纯化 IgG 以及一种能同时识别 ACE2 和 RBD 的小鼠单克隆抗体(mAb 127)对 NETosis 的影响,并研究了其中可能涉及的机制。研究发现,120 名患者的 CR Abs 水平与 COVID-19 的严重程度有关。来自严重 COVID-19 患者的 CR Abs 阳性血清和 IgG 以及 mAb 127 能显著激活人体白细胞,并在 RBD 存在的情况下引发 NETosis。这种由 CR Abs 和 RBD 共存引发的 NETosis 激活了血栓相关细胞,但当 CR Abs 与 ACE2 或 Fc 受体之间的相互作用被破坏时,NETosis 就会消失。我们还发现,在重组 ACE2 或 Src 家族激酶抑制剂达沙替尼存在的情况下,CR Abs 诱导的 NETosis 会受到抑制。此外,我们还发现接种 COVID-19 疫苗不仅能减轻 COVID-19 的严重程度,还能阻止 SARS-CoV-2 感染后 CR Abs 的产生。我们的研究结果提供了CR Abs通过增强NETosis而加剧COVID-19的可能致病作用,强调了ACE2和达沙替尼作为潜在治疗方法的重要性,并支持接种疫苗在降低COVID-19患者疾病严重程度和CR Abs产生方面的益处。
{"title":"Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19","authors":"Kun-Han Hsieh, Chiao-Hsuan Chao, Yi-Ling Cheng, Yen-Chung Lai, Yung-Chun Chuang, Jen-Ren Wang, Sui-Yuan Chang, Yuan-Pin Hung, Yi-Ming Arthur Chen, Wei-Lun Liu, Woei-Jer Chuang, Trai-Ming Yeh","doi":"10.1186/s12929-024-01026-5","DOIUrl":"https://doi.org/10.1186/s12929-024-01026-5","url":null,"abstract":"High levels of neutrophil extracellular trap (NET) formation or NETosis and autoantibodies are related to poor prognosis and disease severity of COVID-19 patients. Human angiotensin-converting enzyme 2 (ACE2) cross-reactive anti-severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain (SARS-CoV-2 RBD) antibodies (CR Abs) have been reported as one of the sources of anti-ACE2 autoantibodies. However, the pathological implications of CR Abs in NET formation remain unknown. In this study, we first assessed the presence of CR Abs in the sera of COVID-19 patients with different severity by serological analysis. Sera and purified IgG from CR Abs positive COVID-19 patients as well as a mouse monoclonal Ab (mAb 127) that can recognize both ACE2 and the RBD were tested for their influence on NETosis and the possible mechanisms involved were studied. An association between CR Abs levels and the severity of COVID-19 in 120 patients was found. The CR Abs-positive sera and IgG from severe COVID-19 patients and mAb 127 significantly activated human leukocytes and triggered NETosis, in the presence of RBD. This NETosis, triggered by the coexistence of CR Abs and RBD, activated thrombus-related cells but was abolished when the interaction between CR Abs and ACE2 or Fc receptors was disrupted. We also revealed that CR Abs-induced NETosis was suppressed in the presence of recombinant ACE2 or the Src family kinase inhibitor, dasatinib. Furthermore, we found that COVID-19 vaccination not only reduced COVID-19 severity but also prevented the production of CR Abs after SARS-CoV-2 infection. Our findings provide possible pathogenic effects of CR Abs in exacerbating COVID-19 by enhancing NETosis, highlighting ACE2 and dasatinib as potential treatments, and supporting the benefit of vaccination in reducing disease severity and CR Abs production in COVID-19 patients.","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"64 1","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140629139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice 用PT320减轻线粒体功能障碍和形态学破坏,延缓MitoPark小鼠的多巴胺变性
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-17 DOI: 10.1186/s12929-024-01025-6
Vicki Wang, Kuan-Yin Tseng, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Lun Lan, Zi-Rong Chen, Kuo-Hsing Ma, Nigel H. Greig, Jin Jung, Ho-II Choi, Lars Olson, Barry J. Hoffer, Yuan-Hao Chen
Mitochondria are essential organelles involved in cellular energy production. Changes in mitochondrial function can lead to dysfunction and cell death in aging and age-related disorders. Recent research suggests that mitochondrial dysfunction is closely linked to neurodegenerative diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonist has gained interest as a potential treatment for Parkinson's disease (PD). However, the exact mechanisms responsible for the therapeutic effects of GLP-1R-related agonists are not yet fully understood. In this study, we explores the effects of early treatment with PT320, a sustained release formulation of the GLP-1R agonist Exenatide, on mitochondrial functions and morphology in a progressive PD mouse model, the MitoPark (MP) mouse. Our findings demonstrate that administration of a clinically translatable dose of PT320 ameliorates the reduction in tyrosine hydroxylase expression, lowers reactive oxygen species (ROS) levels, and inhibits mitochondrial cytochrome c release during nigrostriatal dopaminergic denervation in MP mice. PT320 treatment significantly preserved mitochondrial function and morphology but did not influence the reduction in mitochondria numbers during PD progression in MP mice. Genetic analysis indicated that the cytoprotective effect of PT320 is attributed to a reduction in the expression of mitochondrial fission protein 1 (Fis1) and an increase in the expression of optic atrophy type 1 (Opa1), which is known to play a role in maintaining mitochondrial homeostasis and decreasing cytochrome c release through remodeling of the cristae. Our findings suggest that the early administration of PT320 shows potential as a neuroprotective treatment for PD, as it can preserve mitochondrial function. Through enhancing mitochondrial health by regulating Opa1 and Fis1, PT320 presents a new neuroprotective therapy in PD.
线粒体是参与细胞能量生产的重要细胞器。线粒体功能的变化可导致衰老和与衰老相关疾病的功能障碍和细胞死亡。最新研究表明,线粒体功能障碍与神经退行性疾病密切相关。胰高血糖素样肽-1受体(GLP-1R)激动剂作为一种潜在的帕金森病(PD)治疗药物已引起人们的兴趣。然而,GLP-1R 相关激动剂治疗效果的确切机制尚未完全明了。在这项研究中,我们探讨了GLP-1R激动剂艾塞那肽的缓释制剂PT320早期治疗对进行性帕金森病小鼠模型(MitoPark(MP)小鼠)线粒体功能和形态的影响。我们的研究结果表明,在黑质纹状体多巴胺能剥夺过程中,给小鼠服用临床可转化剂量的PT320可改善酪氨酸羟化酶表达的减少、降低活性氧(ROS)水平并抑制线粒体细胞色素c的释放。PT320治疗能明显保护线粒体的功能和形态,但并不影响线粒体数量的减少。遗传学分析表明,PT320的细胞保护作用归因于线粒体裂变蛋白1(Fis1)表达的减少和视神经萎缩1型(Opa1)表达的增加,后者已知在维持线粒体平衡和通过重塑嵴减少细胞色素c释放方面发挥作用。我们的研究结果表明,早期服用PT320可以保护线粒体功能,因此具有治疗帕金森病的神经保护作用。通过调节 Opa1 和 Fis1 来增强线粒体的健康,PT320 为帕金森病的神经保护疗法提供了一种新思路。
{"title":"Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice","authors":"Vicki Wang, Kuan-Yin Tseng, Tung-Tai Kuo, Eagle Yi-Kung Huang, Kuo-Lun Lan, Zi-Rong Chen, Kuo-Hsing Ma, Nigel H. Greig, Jin Jung, Ho-II Choi, Lars Olson, Barry J. Hoffer, Yuan-Hao Chen","doi":"10.1186/s12929-024-01025-6","DOIUrl":"https://doi.org/10.1186/s12929-024-01025-6","url":null,"abstract":"Mitochondria are essential organelles involved in cellular energy production. Changes in mitochondrial function can lead to dysfunction and cell death in aging and age-related disorders. Recent research suggests that mitochondrial dysfunction is closely linked to neurodegenerative diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonist has gained interest as a potential treatment for Parkinson's disease (PD). However, the exact mechanisms responsible for the therapeutic effects of GLP-1R-related agonists are not yet fully understood. In this study, we explores the effects of early treatment with PT320, a sustained release formulation of the GLP-1R agonist Exenatide, on mitochondrial functions and morphology in a progressive PD mouse model, the MitoPark (MP) mouse. Our findings demonstrate that administration of a clinically translatable dose of PT320 ameliorates the reduction in tyrosine hydroxylase expression, lowers reactive oxygen species (ROS) levels, and inhibits mitochondrial cytochrome c release during nigrostriatal dopaminergic denervation in MP mice. PT320 treatment significantly preserved mitochondrial function and morphology but did not influence the reduction in mitochondria numbers during PD progression in MP mice. Genetic analysis indicated that the cytoprotective effect of PT320 is attributed to a reduction in the expression of mitochondrial fission protein 1 (Fis1) and an increase in the expression of optic atrophy type 1 (Opa1), which is known to play a role in maintaining mitochondrial homeostasis and decreasing cytochrome c release through remodeling of the cristae. Our findings suggest that the early administration of PT320 shows potential as a neuroprotective treatment for PD, as it can preserve mitochondrial function. Through enhancing mitochondrial health by regulating Opa1 and Fis1, PT320 presents a new neuroprotective therapy in PD. ","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"48 1","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140615982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal alterations in brain perfusion and vascular reactivity in the zQ175DN mouse model of Huntington’s disease 亨廷顿症 zQ175DN 小鼠模型脑灌注和血管反应性的纵向变化
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-16 DOI: 10.1186/s12929-024-01028-3
Tamara Vasilkovska, Somaie Salajeghe, Verdi Vanreusel, Johan Van Audekerke, Marlies Verschuuren, Lydiane Hirschler, Jan Warnking, Isabel Pintelon, Dorian Pustina, Roger Cachope, Ladislav Mrzljak, Ignacio Muñoz-Sanjuan, Emmanuel L. Barbier, Winnok H. De Vos, Annemie Van der Linden, Marleen Verhoye
Huntington’s disease (HD) is marked by a CAG-repeat expansion in the huntingtin gene that causes neuronal dysfunction and loss, affecting mainly the striatum and the cortex. Alterations in the neurovascular coupling system have been shown to lead to dysregulated energy supply to brain regions in several neurological diseases, including HD, which could potentially trigger the process of neurodegeneration. In particular, it has been observed in cross-sectional human HD studies that vascular alterations are associated to impaired cerebral blood flow (CBF). To assess whether whole-brain changes in CBF are present and follow a pattern of progression, we investigated both resting-state brain perfusion and vascular reactivity longitudinally in the zQ175DN mouse model of HD. Using pseudo-continuous arterial spin labelling (pCASL) MRI in the zQ175DN model of HD and age-matched wild-type (WT) mice, we assessed whole-brain, resting-state perfusion at 3, 6 and 9 and 13 months of age, and assessed hypercapnia-induced cerebrovascular reactivity (CVR), at 4.5, 6, 9 and 15 months of age. We found increased perfusion in cortical regions of zQ175DN HET mice at 3 months of age, and a reduction of this anomaly at 6 and 9 months, ages at which behavioural deficits have been reported. On the other hand, under hypercapnia, CBF was reduced in zQ175DN HET mice as compared to the WT: for multiple brain regions at 6 months of age, for only somatosensory and retrosplenial cortices at 9 months of age, and brain-wide by 15 months. CVR impairments in cortical regions, the thalamus and globus pallidus were observed in zQ175DN HET mice at 9 months, with whole brain reactivity diminished at 15 months of age. Interestingly, blood vessel density was increased in the motor cortex at 3 months, while average vessel length was reduced in the lateral portion of the caudate putamen at 6 months of age. Our findings reveal early cortical resting-state hyperperfusion and impaired CVR at ages that present motor anomalies in this HD model, suggesting that further characterization of brain perfusion alterations in animal models is warranted as a potential therapeutic target in HD.
亨廷顿氏病(Huntington's disease,HD)的特征是亨廷丁基因中的 CAG 重复扩增,导致神经元功能障碍和丧失,主要影响纹状体和大脑皮层。在包括 HD 在内的多种神经系统疾病中,神经血管耦合系统的改变已被证明会导致脑区能量供应失调,从而有可能引发神经变性过程。特别是,在横断面人类 HD 研究中观察到,血管改变与脑血流(CBF)受损有关。为了评估 CBF 的全脑变化是否存在并遵循进展模式,我们在 zQ175DN HD 小鼠模型中对静息态脑灌注和血管反应性进行了纵向研究。利用伪连续动脉自旋标记(pCASL)核磁共振成像技术,我们对zQ175DN HD模型小鼠和年龄匹配的野生型(WT)小鼠在3、6、9和13个月大时的全脑静息态灌注进行了评估,并在4.5、6、9和15个月大时评估了高碳酸血症诱发的脑血管反应性(CVR)。我们发现,zQ175DN HET 小鼠在 3 个月大时皮质区域的灌注量增加,在 6 个月大和 9 个月大时这种异常有所减少,而在这两个月大时已有行为缺陷的报道。另一方面,在高碳酸血症条件下,zQ175DN HET 小鼠的 CBF 与 WT 小鼠相比有所降低:6 个月大时多个脑区的 CBF 降低,9 个月大时仅体感皮层和回脾皮层的 CBF 降低,15 个月大时整个大脑的 CBF 降低。9 个月大时,zQ175DN HET 小鼠皮质区域、丘脑和丘脑球部的 CVR 受损,15 个月大时整个大脑的反应性减弱。有趣的是,3 个月大时,运动皮层的血管密度增加,而 6 个月大时,尾状核丘脑外侧部分的平均血管长度减少。我们的研究结果揭示了早期皮质静息态高灌注和CVR受损的年龄段,这在HD模型中表现为运动异常,这表明有必要进一步确定动物模型脑灌注改变的特征,并将其作为HD的潜在治疗靶点。
{"title":"Longitudinal alterations in brain perfusion and vascular reactivity in the zQ175DN mouse model of Huntington’s disease","authors":"Tamara Vasilkovska, Somaie Salajeghe, Verdi Vanreusel, Johan Van Audekerke, Marlies Verschuuren, Lydiane Hirschler, Jan Warnking, Isabel Pintelon, Dorian Pustina, Roger Cachope, Ladislav Mrzljak, Ignacio Muñoz-Sanjuan, Emmanuel L. Barbier, Winnok H. De Vos, Annemie Van der Linden, Marleen Verhoye","doi":"10.1186/s12929-024-01028-3","DOIUrl":"https://doi.org/10.1186/s12929-024-01028-3","url":null,"abstract":"Huntington’s disease (HD) is marked by a CAG-repeat expansion in the huntingtin gene that causes neuronal dysfunction and loss, affecting mainly the striatum and the cortex. Alterations in the neurovascular coupling system have been shown to lead to dysregulated energy supply to brain regions in several neurological diseases, including HD, which could potentially trigger the process of neurodegeneration. In particular, it has been observed in cross-sectional human HD studies that vascular alterations are associated to impaired cerebral blood flow (CBF). To assess whether whole-brain changes in CBF are present and follow a pattern of progression, we investigated both resting-state brain perfusion and vascular reactivity longitudinally in the zQ175DN mouse model of HD. Using pseudo-continuous arterial spin labelling (pCASL) MRI in the zQ175DN model of HD and age-matched wild-type (WT) mice, we assessed whole-brain, resting-state perfusion at 3, 6 and 9 and 13 months of age, and assessed hypercapnia-induced cerebrovascular reactivity (CVR), at 4.5, 6, 9 and 15 months of age. We found increased perfusion in cortical regions of zQ175DN HET mice at 3 months of age, and a reduction of this anomaly at 6 and 9 months, ages at which behavioural deficits have been reported. On the other hand, under hypercapnia, CBF was reduced in zQ175DN HET mice as compared to the WT: for multiple brain regions at 6 months of age, for only somatosensory and retrosplenial cortices at 9 months of age, and brain-wide by 15 months. CVR impairments in cortical regions, the thalamus and globus pallidus were observed in zQ175DN HET mice at 9 months, with whole brain reactivity diminished at 15 months of age. Interestingly, blood vessel density was increased in the motor cortex at 3 months, while average vessel length was reduced in the lateral portion of the caudate putamen at 6 months of age. Our findings reveal early cortical resting-state hyperperfusion and impaired CVR at ages that present motor anomalies in this HD model, suggesting that further characterization of brain perfusion alterations in animal models is warranted as a potential therapeutic target in HD.","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"29 1","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140615889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model 抗菌肽比他汀融合内溶菌素 PA90(Tha-PA90)用于控制小鼠模型中的鲍曼不动杆菌感染
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-15 DOI: 10.1186/s12929-024-01027-4
Jeonghyun Lim, Heejoon Myung, Daejin Lim, Miryoung Song
This study addresses the urgent need for infection control agents driven by the rise of drug-resistant pathogens such as Acinetobacter baumannii. Our primary aim was to develop and assess a novel endolysin, Tha-PA90, designed to combat these challenges. Tha-PA90 incorporates an antimicrobial peptide (AMP) called thanatin at its N-terminus, enhancing bacterial outer membrane permeability and reducing host immune responses. PA90 was selected as the endolysin component. The antibacterial activity of the purified Tha-PA90 was evaluated using an in vitro colony-forming unit (CFU) reduction assay and a membrane permeability test. A549 cells were utilized to measure the penetration into the cytosol and the cytotoxicity of Tha-PA90. Finally, infection control was monitored in A. baumannii infected mice following the intraperitoneal administration of Tha-PA90. Tha-PA90 demonstrated remarkable in vitro efficacy, completely eradicating A. baumannii strains, even drug-resistant variants, at a low concentration of 0.5 μM. Notably, it outperformed thanatin, achieving only a < 3-log reduction at 4 μM. Tha-PA90 exhibited 2–3 times higher membrane permeability than a PA90 and thanatin mixture or PA90 alone. Tha-PA90 was found within A549 cells' cytosol with no discernible cytotoxic effects. Furthermore, Tha-PA90 administration extended the lifespan of A. baumannii-infected mice, reducing bacterial loads in major organs by up to 3 logs. Additionally, it decreased proinflammatory cytokine levels (TNF-α and IL-6), reducing the risk of sepsis from rapid bacterial lysis. Our findings indicate that Tha-PA90 is a promising solution for combating drug-resistant A. baumannii. Its enhanced efficacy, low cytotoxicity, and reduction of proinflammatory responses render it a potential candidate for infection control. This study underscores the significance of engineered endolysins in addressing the pressing challenge of drug-resistant pathogens and offers insights into improved infection management strategies.
由于鲍曼不动杆菌等耐药病原体的增加,迫切需要感染控制药物。我们的主要目的是开发和评估一种新型溶菌酶 Tha-PA90,以应对这些挑战。Tha-PA90 在其 N 端加入了一种名为比他汀的抗菌肽 (AMP),可增强细菌外膜的通透性并降低宿主的免疫反应。PA90 被选为内溶菌素成分。纯化的 Tha-PA90 的抗菌活性是通过体外菌落形成单位(CFU)减少试验和膜渗透性试验来评估的。利用 A549 细胞来测量 Tha-PA90 对细胞质的渗透性和细胞毒性。最后,监测了腹腔注射 Tha-PA90 后鲍曼尼氏菌感染小鼠的感染控制情况。Tha-PA90 的体外疗效显著,在 0.5 μM 的低浓度下就能完全清除鲍曼尼氏菌菌株,甚至包括耐药变种。值得注意的是,它的效果优于比他汀,后者在 4 μM 浓度下仅能达到小于 3 个菌落的抑制作用。Tha-PA90 的膜渗透性比 PA90 和比他汀混合物或单独 PA90 高 2-3 倍。在 A549 细胞的细胞质中发现了 Tha-PA90,但没有明显的细胞毒性作用。此外,服用 Tha-PA90 可延长受鲍曼尼氏菌感染的小鼠的寿命,使主要器官中的细菌量减少达 3 个对数。此外,它还能降低促炎细胞因子(TNF-α 和 IL-6)的水平,降低因细菌快速溶解而引发败血症的风险。我们的研究结果表明,Tha-PA90 是一种很有前景的抗耐药性鲍曼尼氏菌解决方案。其增强的疗效、低细胞毒性和减少的促炎反应使其成为控制感染的潜在候选药物。这项研究强调了工程内溶酶体在应对耐药病原体这一紧迫挑战方面的重要意义,并为改进感染管理策略提供了启示。
{"title":"Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model","authors":"Jeonghyun Lim, Heejoon Myung, Daejin Lim, Miryoung Song","doi":"10.1186/s12929-024-01027-4","DOIUrl":"https://doi.org/10.1186/s12929-024-01027-4","url":null,"abstract":"This study addresses the urgent need for infection control agents driven by the rise of drug-resistant pathogens such as Acinetobacter baumannii. Our primary aim was to develop and assess a novel endolysin, Tha-PA90, designed to combat these challenges. Tha-PA90 incorporates an antimicrobial peptide (AMP) called thanatin at its N-terminus, enhancing bacterial outer membrane permeability and reducing host immune responses. PA90 was selected as the endolysin component. The antibacterial activity of the purified Tha-PA90 was evaluated using an in vitro colony-forming unit (CFU) reduction assay and a membrane permeability test. A549 cells were utilized to measure the penetration into the cytosol and the cytotoxicity of Tha-PA90. Finally, infection control was monitored in A. baumannii infected mice following the intraperitoneal administration of Tha-PA90. Tha-PA90 demonstrated remarkable in vitro efficacy, completely eradicating A. baumannii strains, even drug-resistant variants, at a low concentration of 0.5 μM. Notably, it outperformed thanatin, achieving only a < 3-log reduction at 4 μM. Tha-PA90 exhibited 2–3 times higher membrane permeability than a PA90 and thanatin mixture or PA90 alone. Tha-PA90 was found within A549 cells' cytosol with no discernible cytotoxic effects. Furthermore, Tha-PA90 administration extended the lifespan of A. baumannii-infected mice, reducing bacterial loads in major organs by up to 3 logs. Additionally, it decreased proinflammatory cytokine levels (TNF-α and IL-6), reducing the risk of sepsis from rapid bacterial lysis. Our findings indicate that Tha-PA90 is a promising solution for combating drug-resistant A. baumannii. Its enhanced efficacy, low cytotoxicity, and reduction of proinflammatory responses render it a potential candidate for infection control. This study underscores the significance of engineered endolysins in addressing the pressing challenge of drug-resistant pathogens and offers insights into improved infection management strategies.","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"18 1","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140597370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: A novel HIF1α-STIL-FOXM1 axis regulates tumor metastasis 更正:新型 HIF1α-STIL-FOXM1 轴调控肿瘤转移
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-09 DOI: 10.1186/s12929-024-01021-w
Yi-Wei Wang, Shu-Chuan Chen, De-Leung Gu, Yi-Chen Yeh, Jhih-Jie Tsai, Kuo-Tai Yang, Yuh-Shan Jou, Teh-Ying Chou, Tang K. Tang
<p><b>Correction</b><b>: </b><b>J Biomed Sci 29, 24 (2022)</b></p><p><b>https://doi.org/10.1186/s12929-022-00807-0</b></p><br/><p>After publication of this article [1], it was brought to our attention that the figure 6, supplementary figure s5, Supplementary Figure S8 need to be corrected.</p><p>The Incorrect figure 6 is:</p><figure><picture><source srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figa_HTML.png?as=webp" type="image/webp"/><img alt="figure a" aria-describedby="Figa" height="859" loading="lazy" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figa_HTML.png" width="685"/></picture></figure><p>The correct figure 6 is:</p><figure><picture><source srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figb_HTML.png?as=webp" type="image/webp"/><img alt="figure b" aria-describedby="Figb" height="861" loading="lazy" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figb_HTML.png" width="685"/></picture></figure><p>The Incorrect supplementary figure s5 is:</p><figure><picture><source srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figc_HTML.png?as=webp" type="image/webp"/><img alt="figure c" aria-describedby="Figc" height="636" loading="lazy" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figc_HTML.png" width="685"/></picture></figure><p>The correct supplementary figure s5 is:</p><figure><picture><source srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figd_HTML.png?as=webp" type="image/webp"/><img alt="figure d" aria-describedby="Figd" height="636" loading="lazy" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figd_HTML.png" width="685"/></picture></figure><p>The Incorrect Supplementary Figure S8 is:</p><figure><picture><source srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Fige_HTML.png?as=webp" type="image/webp"/><img alt="figure e" aria-describedby="Fige" height="1091" loading="lazy" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Fige_HTML.png" width="685"/></picture></figure><p>The correct Supplementary Figure S8 is:</p><figure><picture><source srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figf_HTML.png?as=webp" type="image/webp"/><img alt="figure f" aria-describedby="Figf" height="1346" loading="lazy" s
更正:J Biomed Sci 29, 24 (2022)https://doi.org/10.1186/s12929-022-00807-0After 本文[1]发表后,我们注意到图6、补充图s5、补充图S8需要更正。不正确的图6是:正确的图6是:不正确的补充图s5是:正确的补充图s5是:不正确的补充图S8是:正确的补充图S8是:已对原文进行了更正。J Biomed Sci. 2022;29:24. https://doi.org/10.1186/s12929-022-00807-0.Article CAS PubMed PubMed Central Google Scholar Download references作者及单位中央研究院生物医学研究所,中央研究院路128号、2 Sec., Taipei, 11529, Taiwan王怡玮、陈淑娟、顾德良、蔡志杰、杨国泰、裘玉山& Tang K. Tang台北荣民总医院病理检验科叶怡辰& Teh-Ying Chou现住址:台北荣民总医院病理检验科:国立屏东大学动物科学系国立屏东科技大学动物科学系,屏东、台湾国立屏东科技大学动物科学系Kuo-Tai Yang作者简介Yi-Wei Wang查看作者发表的论文您也可以在PubMed Google Scholar中搜索该作者Shu-Chuan Chen查看作者发表的论文您也可以在PubMed Google Scholar中搜索该作者De-Leung Gu查看作者发表的论文您也可以在PubMed Google Scholar中搜索该作者Yi-Chen Yeh查看作者发表的论文您也可以在PubMed Google Scholar中搜索该作者Jhih-.Jie TsaiView 作者发表作品您也可以在 PubMed Google Scholar中搜索该作者Kuo-Tai YangView 作者发表作品您也可以在 PubMed Google Scholar中搜索该作者Yuh-Shan JouView 作者发表作品您也可以在 PubMed Google Scholar中搜索该作者Teh-Ying ChouView 作者发表作品您也可以在 PubMed Google Scholar中搜索该作者Tang K. TangView 作者发表作品您也可以在 PubMed Google Scholar中搜索该作者Tang K. TangView 作者发表作品您也可以在 PubMed Google Scholar中搜索该作者Tang查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者通信作者Tang K. Tang.Open Access本文采用知识共享署名4.0国际许可协议进行许可,该协议允许以任何媒介或形式使用、共享、改编、分发和复制,只要您适当注明原作者和来源,提供知识共享许可协议的链接,并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,您需要直接从版权所有者处获得许可。要查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/。除非在数据的信用行中另有说明,否则创作共用公共领域专用免责声明 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文提供的数据。转载与许可引用本文Wang, YW.,Chen, SC.,Gu, DL. et al. Correction:新型 HIF1α-STIL-FOXM1 轴调控肿瘤转移。J Biomed Sci 31, 35 (2024). https://doi.org/10.1186/s12929-024-01021-wDownload citationPublished: 09 April 2024DOI: https://doi.org/10.1186/s12929-024-01021-wShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
{"title":"Correction: A novel HIF1α-STIL-FOXM1 axis regulates tumor metastasis","authors":"Yi-Wei Wang, Shu-Chuan Chen, De-Leung Gu, Yi-Chen Yeh, Jhih-Jie Tsai, Kuo-Tai Yang, Yuh-Shan Jou, Teh-Ying Chou, Tang K. Tang","doi":"10.1186/s12929-024-01021-w","DOIUrl":"https://doi.org/10.1186/s12929-024-01021-w","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Correction&lt;/b&gt;&lt;b&gt;: &lt;/b&gt;&lt;b&gt;J Biomed Sci 29, 24 (2022)&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;https://doi.org/10.1186/s12929-022-00807-0&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p&gt;After publication of this article [1], it was brought to our attention that the figure 6, supplementary figure s5, Supplementary Figure S8 need to be corrected.&lt;/p&gt;&lt;p&gt;The Incorrect figure 6 is:&lt;/p&gt;&lt;figure&gt;&lt;picture&gt;&lt;source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figa_HTML.png?as=webp\" type=\"image/webp\"/&gt;&lt;img alt=\"figure a\" aria-describedby=\"Figa\" height=\"859\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figa_HTML.png\" width=\"685\"/&gt;&lt;/picture&gt;&lt;/figure&gt;&lt;p&gt;The correct figure 6 is:&lt;/p&gt;&lt;figure&gt;&lt;picture&gt;&lt;source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figb_HTML.png?as=webp\" type=\"image/webp\"/&gt;&lt;img alt=\"figure b\" aria-describedby=\"Figb\" height=\"861\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figb_HTML.png\" width=\"685\"/&gt;&lt;/picture&gt;&lt;/figure&gt;&lt;p&gt;The Incorrect supplementary figure s5 is:&lt;/p&gt;&lt;figure&gt;&lt;picture&gt;&lt;source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figc_HTML.png?as=webp\" type=\"image/webp\"/&gt;&lt;img alt=\"figure c\" aria-describedby=\"Figc\" height=\"636\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figc_HTML.png\" width=\"685\"/&gt;&lt;/picture&gt;&lt;/figure&gt;&lt;p&gt;The correct supplementary figure s5 is:&lt;/p&gt;&lt;figure&gt;&lt;picture&gt;&lt;source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figd_HTML.png?as=webp\" type=\"image/webp\"/&gt;&lt;img alt=\"figure d\" aria-describedby=\"Figd\" height=\"636\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figd_HTML.png\" width=\"685\"/&gt;&lt;/picture&gt;&lt;/figure&gt;&lt;p&gt;The Incorrect Supplementary Figure S8 is:&lt;/p&gt;&lt;figure&gt;&lt;picture&gt;&lt;source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Fige_HTML.png?as=webp\" type=\"image/webp\"/&gt;&lt;img alt=\"figure e\" aria-describedby=\"Fige\" height=\"1091\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Fige_HTML.png\" width=\"685\"/&gt;&lt;/picture&gt;&lt;/figure&gt;&lt;p&gt;The correct Supplementary Figure S8 is:&lt;/p&gt;&lt;figure&gt;&lt;picture&gt;&lt;source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12929-024-01021-w/MediaObjects/12929_2024_1021_Figf_HTML.png?as=webp\" type=\"image/webp\"/&gt;&lt;img alt=\"figure f\" aria-describedby=\"Figf\" height=\"1346\" loading=\"lazy\" s","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"243 1","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140597474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significance of hepatitis B virus capsid dephosphorylation via polymerase. 乙型肝炎病毒通过聚合酶去磷酸化的意义
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-04-01 DOI: 10.1186/s12929-024-01022-9
Chih-Hsu Chang, Chiaho Shih

Background: It is generally believed that hepatitis B virus (HBV) core protein (HBc) dephosphorylation (de-P) is important for viral DNA synthesis and virion secretion. HBV polymerase contains four domains for terminal protein, spacer, reverse transcriptase, and RNase H activities.

Methods: HBV Polymerase mutants were transfected into HuH-7 cells and assayed for replication and HBc de-P by the Phos-tag gel analysis. Infection assay was performed by using a HepG2-NTCP-AS2 cell line.

Results: Here, we show that a novel phosphatase activity responsible for HBc de-P can be mapped to the C-terminal domain of the polymerase overlapping with the RNase H domain. Surprisingly, while HBc de-P is crucial for viral infectivity, it is essential for neither viral DNA synthesis nor virion secretion. The potential origin, significance, and mechanism of this polymerase-associated phosphatase activity are discussed in the context of an electrostatic homeostasis model. The Phos-tag gel analysis revealed an intriguing pattern of "bipolar distribution" of phosphorylated HBc and a de-P HBc doublet.

Conclusions: It remains unknown if such a polymerase-associated phosphatase activity can be found in other related biosystems. This polymerase-associated phosphatase activity could be a druggable target in clinical therapy for hepatitis B.

背景:一般认为,乙型肝炎病毒(HBV)核心蛋白(HBc)去磷酸化(de-P)对病毒 DNA 合成和病毒分泌很重要。方法:将 HBV 聚合酶突变体转染到 HuH-7 细胞中,用 Phos-tag 凝胶分析法检测其复制和 HBc 去磷酸化情况。使用 HepG2-NTCP-AS2 细胞系进行感染检测:结果:我们在这里发现,一种新型磷酸酶活性可被映射到与 RNase H 结构域重叠的聚合酶 C 端结构域上,这种磷酸酶活性可导致 HBc 脱 P。令人惊讶的是,虽然 HBc de-P 对病毒的感染性至关重要,但它对病毒 DNA 合成和病毒分泌都不重要。本文结合静电平衡模型讨论了这种聚合酶相关磷酸酶活性的潜在来源、意义和机制。Phos-tag 凝胶分析揭示了磷酸化 HBc 和去磷酸化 HBc 双顶体的 "双极分布 "模式:结论:这种聚合酶相关磷酸酶活性是否存在于其他相关生物系统中仍是未知数。这种聚合酶相关磷酸酶活性可能是临床治疗乙型肝炎的药物靶点。
{"title":"Significance of hepatitis B virus capsid dephosphorylation via polymerase.","authors":"Chih-Hsu Chang, Chiaho Shih","doi":"10.1186/s12929-024-01022-9","DOIUrl":"10.1186/s12929-024-01022-9","url":null,"abstract":"<p><strong>Background: </strong>It is generally believed that hepatitis B virus (HBV) core protein (HBc) dephosphorylation (de-P) is important for viral DNA synthesis and virion secretion. HBV polymerase contains four domains for terminal protein, spacer, reverse transcriptase, and RNase H activities.</p><p><strong>Methods: </strong>HBV Polymerase mutants were transfected into HuH-7 cells and assayed for replication and HBc de-P by the Phos-tag gel analysis. Infection assay was performed by using a HepG2-NTCP-AS2 cell line.</p><p><strong>Results: </strong>Here, we show that a novel phosphatase activity responsible for HBc de-P can be mapped to the C-terminal domain of the polymerase overlapping with the RNase H domain. Surprisingly, while HBc de-P is crucial for viral infectivity, it is essential for neither viral DNA synthesis nor virion secretion. The potential origin, significance, and mechanism of this polymerase-associated phosphatase activity are discussed in the context of an electrostatic homeostasis model. The Phos-tag gel analysis revealed an intriguing pattern of \"bipolar distribution\" of phosphorylated HBc and a de-P HBc doublet.</p><p><strong>Conclusions: </strong>It remains unknown if such a polymerase-associated phosphatase activity can be found in other related biosystems. This polymerase-associated phosphatase activity could be a druggable target in clinical therapy for hepatitis B.</p>","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"31 1","pages":"34"},"PeriodicalIF":11.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10983652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140335807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of TRAIL receptor with phosphatase SHP-1 enables repressing T cell receptor signaling and T cell activation through inactivating Lck. TRAIL 受体与磷酸酶 SHP-1 的结合可通过使 Lck 失活来抑制 T 细胞受体信号传导和 T 细胞活化。
IF 11 2区 医学 Q1 CELL BIOLOGY Pub Date : 2024-03-27 DOI: 10.1186/s12929-024-01023-8
I-Tsu Chyuan, Hsiu-Jung Liao, Tse-Hua Tan, Huai-Chia Chuang, Yu-Chuan Chu, Meng-Hsun Pan, Chien-Sheng Wu, Ching-Liang Chu, Bor-Ching Sheu, Ping-Ning Hsu

Background: T cell receptor (TCR) signaling and T cell activation are tightly regulated by gatekeepers to maintain immune tolerance and avoid autoimmunity. The TRAIL receptor (TRAIL-R) is a TNF-family death receptor that transduces apoptotic signals to induce cell death. Recent studies have indicated that TRAIL-R regulates T cell-mediated immune responses by directly inhibiting T cell activation without inducing apoptosis; however, the distinct signaling pathway that regulates T cell activation remains unclear. In this study, we screened for intracellular TRAIL-R-binding proteins within T cells to explore the novel signaling pathway transduced by TRAIL-R that directly inhibits T cell activation.

Methods: Whole-transcriptome RNA sequencing was used to identify gene expression signatures associated with TRAIL-R signaling during T cell activation. High-throughput screening with mass spectrometry was used to identify the novel TRAIL-R binding proteins within T cells. Co-immunoprecipitation, lipid raft isolation, and confocal microscopic analyses were conducted to verify the association between TRAIL-R and the identified binding proteins within T cells.

Results: TRAIL engagement downregulated gene signatures in TCR signaling pathways and profoundly suppressed phosphorylation of TCR proximal tyrosine kinases without inducing cell death. The tyrosine phosphatase SHP-1 was identified as the major TRAIL-R binding protein within T cells, using high throughput mass spectrometry-based proteomics analysis. Furthermore, Lck was co-immunoprecipitated with the TRAIL-R/SHP-1 complex in the activated T cells. TRAIL engagement profoundly inhibited phosphorylation of Lck (Y394) and suppressed the recruitment of Lck into lipid rafts in the activated T cells, leading to the interruption of proximal TCR signaling and subsequent T cell activation.

Conclusions: TRAIL-R associates with phosphatase SHP-1 and transduces a unique and distinct immune gatekeeper signal to repress TCR signaling and T cell activation via inactivating Lck. Thus, our results define TRAIL-R as a new class of immune checkpoint receptors for restraining T cell activation, and TRAIL-R/SHP-1 axis can serve as a potential therapeutic target for immune-mediated diseases.

背景:T细胞受体(TCR)信号传导和T细胞活化受到守门员的严格调控,以维持免疫耐受并避免自身免疫。TRAIL 受体(TRAIL-R)是 TNF 家族的死亡受体,可传递凋亡信号以诱导细胞死亡。最近的研究表明,TRAIL-R 通过直接抑制 T 细胞活化而不诱导细胞凋亡来调节 T 细胞介导的免疫反应;然而,调节 T 细胞活化的独特信号通路仍不清楚。在这项研究中,我们筛选了T细胞内的TRAIL-R结合蛋白,以探索TRAIL-R直接抑制T细胞活化的新型信号通路:方法:采用全转录组RNA测序技术鉴定T细胞活化过程中与TRAIL-R信号转导相关的基因表达特征。方法:采用全转录组 RNA 测序鉴定 T 细胞活化过程中与 TRAIL-R 信号相关的基因表达特征。采用质谱法进行高通量筛选,鉴定 T 细胞内的新型 TRAIL-R 结合蛋白。共免疫沉淀、脂筏分离和共聚焦显微镜分析验证了T细胞内TRAIL-R与已确定的结合蛋白之间的关联:结果:TRAIL 参与下调了 TCR 信号通路中的基因特征,并显著抑制了 TCR 近端酪氨酸激酶的磷酸化,但不会诱导细胞死亡。通过基于高通量质谱的蛋白质组学分析,发现酪氨酸磷酸酶SHP-1是T细胞中主要的TRAIL-R结合蛋白。此外,在活化的T细胞中,Lck与TRAIL-R/SHP-1复合物共免疫沉淀。TRAIL的参与极大地抑制了Lck(Y394)的磷酸化,并抑制了Lck在活化T细胞脂质筏中的招募,从而导致近端TCR信号的中断和随后的T细胞活化:结论:TRAIL-R与磷酸酶SHP-1结合,通过抑制Lck的活性,传递一种独特的免疫守门员信号,抑制TCR信号的传递和T细胞的活化。因此,我们的研究结果将 TRAIL-R 定义为抑制 T 细胞活化的一类新型免疫检查点受体,TRAIL-R/SHP-1 轴可作为免疫介导疾病的潜在治疗靶点。
{"title":"Association of TRAIL receptor with phosphatase SHP-1 enables repressing T cell receptor signaling and T cell activation through inactivating Lck.","authors":"I-Tsu Chyuan, Hsiu-Jung Liao, Tse-Hua Tan, Huai-Chia Chuang, Yu-Chuan Chu, Meng-Hsun Pan, Chien-Sheng Wu, Ching-Liang Chu, Bor-Ching Sheu, Ping-Ning Hsu","doi":"10.1186/s12929-024-01023-8","DOIUrl":"10.1186/s12929-024-01023-8","url":null,"abstract":"<p><strong>Background: </strong>T cell receptor (TCR) signaling and T cell activation are tightly regulated by gatekeepers to maintain immune tolerance and avoid autoimmunity. The TRAIL receptor (TRAIL-R) is a TNF-family death receptor that transduces apoptotic signals to induce cell death. Recent studies have indicated that TRAIL-R regulates T cell-mediated immune responses by directly inhibiting T cell activation without inducing apoptosis; however, the distinct signaling pathway that regulates T cell activation remains unclear. In this study, we screened for intracellular TRAIL-R-binding proteins within T cells to explore the novel signaling pathway transduced by TRAIL-R that directly inhibits T cell activation.</p><p><strong>Methods: </strong>Whole-transcriptome RNA sequencing was used to identify gene expression signatures associated with TRAIL-R signaling during T cell activation. High-throughput screening with mass spectrometry was used to identify the novel TRAIL-R binding proteins within T cells. Co-immunoprecipitation, lipid raft isolation, and confocal microscopic analyses were conducted to verify the association between TRAIL-R and the identified binding proteins within T cells.</p><p><strong>Results: </strong>TRAIL engagement downregulated gene signatures in TCR signaling pathways and profoundly suppressed phosphorylation of TCR proximal tyrosine kinases without inducing cell death. The tyrosine phosphatase SHP-1 was identified as the major TRAIL-R binding protein within T cells, using high throughput mass spectrometry-based proteomics analysis. Furthermore, Lck was co-immunoprecipitated with the TRAIL-R/SHP-1 complex in the activated T cells. TRAIL engagement profoundly inhibited phosphorylation of Lck (Y394) and suppressed the recruitment of Lck into lipid rafts in the activated T cells, leading to the interruption of proximal TCR signaling and subsequent T cell activation.</p><p><strong>Conclusions: </strong>TRAIL-R associates with phosphatase SHP-1 and transduces a unique and distinct immune gatekeeper signal to repress TCR signaling and T cell activation via inactivating Lck. Thus, our results define TRAIL-R as a new class of immune checkpoint receptors for restraining T cell activation, and TRAIL-R/SHP-1 axis can serve as a potential therapeutic target for immune-mediated diseases.</p>","PeriodicalId":15365,"journal":{"name":"Journal of Biomedical Science","volume":"31 1","pages":"33"},"PeriodicalIF":11.0,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10967194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Biomedical Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1